ARTICLE | Clinical News

Gilead's TAF-based regimen meets Phase III endpoint

September 25, 2014 2:25 AM UTC

Gilead Sciences Inc. (NASDAQ:GILD) said a tenofovir alafenamide (TAF)-based regimen met the primary endpoint of non-inferiority to Gilead's Stribild in two identical Phase III trials to treat HIV-1 infection in treatment-naive patients.

In Study 104, 93.1% of patients receiving a once-daily single-tablet regimen of TAF plus elvitegravir/cobicistat/emtricitabine achieved HIV RNA levels of less than 50 copies/mL at week 48 compared with 92.4% of those taking Stribild elvitegravir/cobicistat/emtricitabine/tenofovir. In Study 111, 91.6% of patients receiving the TAF combination achieved the measure compared with 88.5% of Stribild patients. ...